You’ve developed a new Alzheimer’s drug that disrupts the abnormal amyloid pathway that results in Alzheimer’s disease. In its current formulation, the octanol/water partition coefficient of your drug is quite low, completely lipophobic. Why won’t this drug work in vivo?
All model papers offered by Graduatenursingtutors.com must be properly referenced. We do not encourage or endorse any activities that violate applicable law or any college or university policies.